Chicago—Now that rofecoxib has been pulled
from the market due to life-threatening adverse cardiovascular events, which
had reportedly been evident 4 years ago, patients and physicians are left
with many questions regarding the safety of other drugs that preferentially
inhibit the cyclooxygenase-2 (COX-2) enzyme and the shortcomings in the government’s
drug monitoring system in general.
Hampton T. Experts Point to Lessons Learned From Controversy Over Rofecoxib Safety. JAMA. 2005;293(4):413-414. doi:10.1001/jama.293.4.413